Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

March 31, 2006

Conditions
Peripheral Vascular Disease
Interventions
DRUG

Fibrin sealant (FS2)

Trial Locations (17)

12208

Alband Medical Center, Albany

14209

Millarad Fillmore Hospital, SUNY, Buffalo

22908

UVA Health System, Charlottesville

23503

Vascular and Transplant Specialists, Norfolk

32216

Baptist Medical Center, Jacksonville

Memorial Hospital, Jacksonville

33103

Jackson Memorial Hospital, Miami

37232

Vanderbilt Univ Medical Center, Nashville

43606

Jobst Vascular Center, Toledo

50314

Iowa Heart Center, Des Moines

62702

Southern Illinois University School of Medicine, Springfield

01655

Univ of Mass Medical Center, Worcester

07601

Hackensack Medical Center, Hackensack

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

B9 5SS

Birmingham Heartlands Hospital, Birmingham

EH16 4SA

Royal Infirmary of Edinburgh, Edinburgh

HU3 2JZ

Hull Royal Infirmary, Hull

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OMRIX Biopharmaceuticals

INDUSTRY

lead

Ethicon, Inc.

INDUSTRY

NCT00154141 - Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures | Biotech Hunter | Biotech Hunter